ASRS 2026 · Retina biotech comparative report

ASRS 2026 Retina Showdown: New Data Put $FDMT, $RGNX and $KLRS Under the Spotlight

Three small- and mid-cap biotechnology companies are chasing the same strategic prize—durable retinal-disease control with fewer injections—but they are using different technologies, different delivery routes and radically different levels of clinical evidence.

Published July 19, 2026 · Updated before the July 20 U.S. market open · Clinical data, financing and catalyst analysis · Educational research only

What arrived at ASRS—and why Monday’s tape may be complicated

The American Society of Retina Specialists annual meeting created a concentrated set of readouts across wet age-related macular degeneration, diabetic retinopathy and sustained anti-VEGF therapy. The timing matters. Both 4DMT and REGENXBIO released their principal updates on Saturday, July 18, after the regular U.S. session had ended. The market therefore had not yet established a clean price for the new clinical information when this report was prepared.

Kalaris was different. Its expanded Phase 1a dataset arrived Friday morning and traded during the session. REGENXBIO’s share price was also processing a separate—and financially more immediate—event: the company priced a roughly $100 million public offering at $9.00 per share-equivalent on Friday. That financing can overwhelm a favorable weekend data headline because it resets ownership before the clinical result is judged.

That creates three different Monday setups:

• $FDMT: a relatively clean reaction to new two-year durability and safety data, although expectations may already include confidence in the ongoing Phase 3 program.
• $RGNX: a mixed reaction in which five-year clinical durability competes with the overhang of newly issued shares and pre-funded warrants.
• $KLRS: a second-stage interpretation of Friday’s move, with investors deciding how much value to assign to a small uncontrolled dataset and whether manufacturing changes truly contain inflammation risk.

The programs are not directly comparable

Cross-trial ranking is especially hazardous here. $RGNX enrolled previously treated, frequently injected patients in early wet-AMD cohorts and uses a surgical subretinal procedure. $KLRS currently highlights 17 treatment-naïve patients in an open-label first-in-human study. $FDMT’s headline injection reduction is calculated against projected on-label aflibercept 2 mg every eight weeks, not a contemporaneous randomized control. Patient history, rescue criteria, loading doses, baseline disease activity, follow-up duration and delivery route all differ.

Why retinal durability is valuable—and why it is difficult

Standard anti-VEGF therapy transformed wet AMD, but its real-world weakness is operational. Patients may require injections every one or two months, along with monitoring visits, caregiver support and clinic capacity. Longer-acting approved agents have extended intervals for many patients, yet undertreatment and loss to follow-up remain major practical problems. A one-time genetic medicine or a highly durable injectable could reduce this burden substantially.

However, longer biological activity also changes the risk. A conventional injection can be stopped. A gene therapy designed to produce an anti-VEGF protein for years cannot be switched off easily. Safety, dose control, inflammation, delivery precision and the ability to rescue under-treated disease become central. For a repeatable protein therapy such as TH103, the challenge is different: enough ocular residence to extend the interval, but acceptable inflammation and manufacturing consistency across repeated exposure.

The competitive bar is rising as well. Approved products such as Eylea and Vabysmo already offer extended dosing for subsets of patients. Ocular Therapeutix is advancing the axitinib implant AXPAXLI through Phase 3, while EyePoint is developing DURAVYU. A new program does not merely need to beat monthly injections in theory; it must offer a clinically and commercially meaningful improvement over a standard of care that continues to evolve.

$FDMT: the strongest new two-year wet-AMD signal

What PRISM Phase 2b reported

4D Molecular Therapeutics’ PRISM Phase 2b study enrolled 45 patients: 30 received 4D-150 at the Phase 3 dose of 3E10 vector genomes per eye and 15 received 1E10. Through two years, the company reported maintained visual acuity and control of central subfield thickness after one intravitreal injection.

Across the overall Phase 2b cohort, the company calculated a 78% reduction in supplemental anti-VEGF injection burden, with 2.7 mean supplemental injections versus 12.0 projected injections under an on-label aflibercept 2 mg every-eight-week regimen. In the 15-patient recently diagnosed subgroup treated at the Phase 3 dose, the reported reduction reached 87%, with 1.6 mean supplemental injections versus the same projected 12.0 benchmark.

The dose response favored 3E10, supporting the dose selected for the 4FRONT pivotal program. That consistency matters: when a company has already committed hundreds of patients to Phase 3, the most useful new Phase 2 information is evidence that the chosen dose continues to separate and remains tolerable with longer follow-up.

What is genuinely encouraging

• Duration: two-year follow-up reduces the risk that an initially strong gene-expression signal fades quickly.
• Administration: intravitreal delivery is familiar to retinal specialists and operationally easier than subretinal surgery.
• Dose coherence: the Phase 3 dose showed the stronger effect, which is more useful than a post hoc result at a dose no longer being developed.
• Safety follow-up: at the Phase 3 dose, across PRISM Phase 1/2a and Phase 2b, two of 71 patients had mild 1+ intraocular inflammation. Both events were transient and occurred within roughly the first 28 weeks; the company reported no new inflammation after week 28 with follow-up ranging from two to more than four years.

4DMT also reported no treatment-related hypotony, endophthalmitis, vasculitis, retinal vasculitis or choroidal effusions in that pooled Phase 3-dose safety population. This does not eliminate rare-event risk—71 patients cannot characterize very uncommon complications—but the long observation period is directionally reassuring.

What the headline does not prove

The 78% and 87% figures are not randomized efficacy estimates. The comparator is a projected on-label injection schedule. In real clinical practice, injection frequency depends on disease activity, clinician behavior and treat-and-extend protocols. The recently diagnosed subgroup contains only 15 patients, which makes an apparently superior percentage unstable.

The decisive evidence will come from the two randomized Phase 3 studies. 4FRONT-1 completed enrollment and randomized 523 participants; topline data are expected in the first half of 2027. 4FRONT-2 completed enrollment roughly four months early with more than 500 participants, with final randomization targeted for the third quarter of 2026 and 52-week topline data expected in the second half of 2027.

That program size is the real source of $FDMT’s de-risking—and also the source of its next binary risk. A pivotal trial can reveal smaller efficacy, different rescue-injection behavior or less favorable safety than a modest Phase 2 study.

$RGNX: the longest follow-up and the closest pivotal answer

Five-year wet-AMD durability

REGENXBIO’s surabgene lomparvovec—sura-vec, formerly ABBV-RGX-314—uses an AAV8 vector to turn retinal cells into a source of an anti-VEGF antibody fragment. In wet AMD, the program uses subretinal delivery, an operating-room procedure performed during vitrectomy.

At ASRS, the company reported five-year follow-up from Phase I/IIa Cohorts 3 and 4 at doses similar to those used in the pivotal program. Participants had stable to improved visual acuity and meaningful reductions in anti-VEGF treatment burden through five years, excluding one participant with polypoidal choroidal vasculopathy described as refractory to anti-VEGF therapy. No new long-term safety signal was identified, and no intraocular inflammation was observed among participants who completed the Phase I/IIa study.

Five years is the longest duration in this three-company comparison. It supports the biological premise that ocular AAV expression can remain clinically active for years. But it is still supportive evidence from early cohorts—not the pivotal answer. The company also presented a one-year analysis against matched real-world external controls. That comparison suggested better vision preservation, lower retinal-thickness fluctuation and fewer injections, but an external control cannot remove selection bias as reliably as randomization.

The Q4 2026 pivotal event

The investment case now compresses toward two active-controlled studies:

• ATMOSPHERE: sura-vec versus ranibizumab, with non-inferiority on change in best-corrected visual acuity at week 54.
• ASCENT: sura-vec versus aflibercept, with non-inferiority on change in best-corrected visual acuity at one year.

Together the trials enrolled more than 1,200 participants across more than 200 sites. Topline data are expected in Q4 2026. Secondary measures include central retinal thickness, safety and the need for supplemental anti-VEGF injections.

A statistically successful non-inferiority result would validate the largest late-stage ocular gene-therapy dataset in the group. Commercial interpretation will require more than the primary endpoint, however. Investors will need to see how many patients remain rescue-free, the distribution rather than only the average number of injections, surgical and postoperative complications, inflammation, and whether outcomes are consistent across the two controls.

Diabetic retinopathy adds a different route

In the Phase II ALTITUDE study, sura-vec was delivered through an in-office suprachoroidal procedure. At the Phase IIb/III dose, 55% of 17 participants achieved a greater-than-two-step improvement on the Diabetic Retinopathy Severity Scale without additional treatment at 2.5 years, while 70% experienced no vision-threatening event. No intraocular inflammation was observed through 2.5 years with a short course of prophylactic topical steroids.

This is intriguing but small-sample evidence. The confirmatory path has only just begun: the first patient in the Phase IIb/III NAAVIGATE trial was dosed in June, triggering a $100 million AbbVie milestone expected in July. The Phase IIb portion is expected to enroll approximately 135 U.S. patients.

The AbbVie structure improves economics—but does not remove financing risk

REGENXBIO received $370 million upfront when the AbbVie collaboration closed and is eligible for up to $1.38 billion in additional milestones. U.S. profits are shared 50/50, while REGENXBIO receives tiered royalties outside the United States. AbbVie brings commercialization capacity, but REGENXBIO remains exposed to trial, manufacturing and funding needs.

On July 17, the company priced 10,003,889 common shares at $9.00 and 1,111,111 pre-funded warrants at $8.9999, for approximately $100 million in gross proceeds before fees. Relative to 51,697,621 shares outstanding on May 8, the base deal adds approximately 21.5% in new share-equivalents. Put differently, a holder who did not participate would own about 17.7% less of the post-deal company, before any underwriter option. If the underwriters fully exercise their option for another 1,667,250 shares, the share-equivalent expansion would be roughly 24.7% versus that May base and the corresponding ownership dilution about 19.8%.

$KLRS: compelling early pharmacology, but still an early-stage bet

What TH103 showed after one dose

Kalaris’ TH103 is not a gene therapy. It is an engineered VEGF trap designed to remain in the eye longer while reducing systemic exposure. The expanded Phase 1a analysis includes 17 treatment-naïve wet-AMD patients in the single-ascending-dose study plus three treatment-experienced patients in a safety cohort; all 20 completed six months of follow-up.

Among the 17 treatment-naïve patients:

• 41% received their first rescue treatment at month four or later;
• 35% reached month five or later before first rescue;
• 29% required no additional anti-VEGF treatment during the full six months;
• at month one, mean best-corrected visual acuity improved by 9.2 letters and mean central subfield thickness improved by 118 microns;
• 93% had a reduction in central-subfield intraretinal fluid.

The three treatment-experienced patients extended their average retreatment interval by approximately two months relative to prior therapy. Pharmacokinetic analysis showed plasma peak concentration 27 to 53 times lower than a leading anti-VEGF agent on a molar-equivalent basis. Kalaris interprets that result as evidence of greater intraocular retention.

That interpretation is biologically plausible, but investors should keep the evidentiary hierarchy straight: lower systemic Cmax is supportive pharmacology, not clinical proof of six-month efficacy. The clinical durability numbers are more relevant, and they remain uncontrolled observations in a very small population.

The inflammation and manufacturing issue

The original Phase 1a dataset included two transient mild-to-moderate intraocular-inflammation cases at 2.5 mg. Kalaris attributed them to a retained host-cell protein impurity and added purification steps. Six participants subsequently treated at 2.5 mg with process-adjusted material had no inflammation. One transient inflammation event occurred at 5 mg and resolved without sequelae.

The company’s SEC risk disclosures are appropriately more cautious than a headline. They acknowledge inflammation cases across Phase 1a and Phase 1b/2, generally mild or moderate and responsive to topical or oral steroids, while stating the belief that retained impurities were responsible. Manufacturing refinements delayed the repeated-dose program and moved preliminary Phase 1b/2 data from the second half of 2026 into the first half of 2027.

For an intravitreal medicine intended to be given repeatedly, the decisive safety question is not whether a small post-change cohort remained clean after one exposure. It is whether consistent commercial-scale material remains tolerable across multiple monthly loading doses and later maintenance dosing.

What the next study must establish

The ongoing Phase 1b/2 study is expected to enroll roughly 60 to 80 patients and administer four monthly loading doses. Preliminary data are expected in the first half of 2027 and are intended to support dose selection for a future pivotal program. Kalaris has indicated that a Phase 3 study could begin by the end of 2027 if the data and regulatory process support it.

A successful update needs to show three things simultaneously: repeat-dose safety after the manufacturing changes, preserved or improved vision and anatomy, and a meaningful extension of time to rescue after loading. If one leg fails, the early single-dose signal will be difficult to value.

Evidence-quality scorecard

Cash, runway and dilution: the second clinical endpoint

Biotechnology investors do not own clinical percentages in isolation; they own percentages per share after the capital required to reach the next dataset. The three balance sheets are therefore part of the clinical comparison.

$FDMT has the cleanest financial alignment with its pivotal timeline. $RGNX has bought additional time and receives valuable partner funding, but shareholders paid for part of that extension through immediate dilution. $KLRS can reach its first repeated-dose update under current guidance, yet a registrational wet-AMD program would require substantially more time and capital if TH103 advances.

Catalyst map: what changes each thesis next

Dates are company targets, not guarantees. Enrollment, manufacturing, regulator feedback and data-cleaning timelines can move.

Bull, base and bear paths—without price targets

$FDMT scenario map

• Bull: Phase 3 reproduces maintained vision with a large, clinically meaningful rescue-injection reduction; low inflammation persists at scale; intravitreal administration supports adoption.
• Base: efficacy is sufficient for continued development but less dramatic than the projected-comparator Phase 2 headline; investors debate differentiation versus longer-acting approved drugs and implants.
• Bear: pivotal non-inferiority, rescue burden, safety or manufacturing outcomes fail to support the intended product profile. Because 4D-150 dominates the valuation narrative, concentration risk is substantial.

$RGNX scenario map

• Bull: both pivotal studies meet non-inferiority with convincing long-term injection reduction and manageable procedure-related safety; AbbVie validates a credible specialist-launch pathway.
• Base: trials meet the primary endpoint but commercial debate centers on surgery, site training and which high-burden patients justify the procedure.
• Bear: one or both pivotal studies miss, rescue injections dilute the value proposition, or safety/logistics constrain uptake. The new offering protects liquidity but spreads any future value over more share-equivalents.

$KLRS scenario map

• Bull: refined manufacturing prevents recurrent inflammation, repeated dosing confirms strong anatomy and vision, and a meaningful fraction of patients sustain four-to-six-month intervals.
• Base: TH103 remains active and tolerable but produces durability closer to existing options, requiring a larger controlled study before differentiation is visible.
• Bear: inflammation recurs, batch consistency remains problematic, or the early efficacy signal regresses toward the mean in a larger population. Timeline slippage increases financing pressure.

The critical comparison investors should make

4DMT has the best combination of fresh clinical clarity, practical delivery and financing. The Phase 2b result is still not randomized, but the company has chosen a dose, accumulated multi-year safety follow-up and placed two large Phase 3 trials on the calendar with enough reported runway to reach them.

REGENXBIO has the most important near-term validation event. Five-year durability is scientifically meaningful, and AbbVie’s involvement improves both execution and economics. Yet subretinal surgery is a real commercial constraint, and the July equity raise means the clinical upside must now be divided across a larger ownership base. Q4 data can answer questions that no external-control analysis can.

Kalaris has the most asymmetric early story. A durable, repeatable intravitreal VEGF trap could be commercially attractive, especially if systemic exposure remains low. But 17 treatment-naïve patients cannot establish a product profile, and manufacturing-linked inflammation is not resolved until a larger repeated-dose dataset stays clean.

Primary sources and further reading

• 4DMT: PRISM Phase 2b two-year 4D-150 data, July 18, 2026
• 4DMT: Q1 2026 financial results and operational update
• REGENXBIO: five-year wet-AMD and 2.5-year DR sura-vec data, July 18, 2026
• REGENXBIO: NAAVIGATE first patient and $100 million AbbVie milestone
• REGENXBIO: July 2026 public-offering terms
• REGENXBIO: Q1 2026 Form 10-Q
• REGENXBIO: AbbVie eye-care collaboration economics
• Kalaris: expanded TH103 Phase 1a six-month data, July 17, 2026
• Kalaris: initial Phase 1a data and manufacturing-process changes
• Kalaris: Q1 2026 Form 10-Q
• Merlintrader: July 17 Biotech Radar on $KLRS and the $RGNX financing
• Merlintrader: updated $RGNX stock hub and 2026–2027 catalyst map

Disclaimer: This article is for educational and informational purposes only. It is not investment research, individualized financial advice, a recommendation, or an offer to buy or sell any security under U.S., EU or Italian law. Biotechnology securities can be highly volatile and may lose substantial value following clinical, regulatory, manufacturing or financing events. Trial comparisons are limited by differences in design, population, endpoints and follow-up. Company timelines and forward-looking statements may change. Readers should review primary filings and consult an appropriately authorized professional before making financial decisions.